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Abstract
Hiccups, medically referred as singultus, is a condition that results from involuntary contraction of the
diaphragm and intercostal muscles. Singultus is usually a self-limiting condition which typically lasts less
than 48 hours but in rare cases, can persist greater than 48 hours. This is a case of a 48 year-old male
who was prescribed dexamethasone for COVID-19 but developed intractable singultus for two weeks.
Patient was unable to tolerate diet due to intractable singultus leading to vomiting. He underwent various
non-pharmacological maneuvers and pharmacotherapy without resolution. Dexamethasone- induced
hiccups have been reported as an under recognized side effect of dexamethasone. Despite
discontinuation of offending agent, patient’s singultus persisted. The patient achieved resolution of
singultus with a combination of baclofen and olanzapine. This case provides additional literature during
this COVID-19 pandemic while dexamethasone is being used as the first line management.
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Abstract
Hiccups, medically referred as singultus, is a condition that results from involuntary contraction of the diaphragm and
intercostal muscles. Singultus is usually a self-limiting condition which typically lasts less than 48 h but in rare cases, can
persist greater than 48 h. This is a case of a 48 year-old male who was prescribed dexamethasone for COVID-19 but
developed intractable singultus for two weeks. Patient was unable to tolerate diet due to intractable singultus leading to
vomiting. He underwent various non-pharmacological maneuvers and pharmacotherapy without resolution. Dexamethasone-induced hiccups have been reported as an under recognized side effect of dexamethasone. Despite discontinuation of offending agent, patient's singultus persisted. The patient achieved resolution of singultus with a
combination of baclofen and olanzapine. This case provides additional literature during this COVID-19 pandemic while
dexamethasone is being used as the ﬁrst line management.
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1. Case presentation

A

48-year-old male with no signiﬁcant past
medical history initially presented to the
Emergency Department (ED) with a dry cough.
Symptoms were highly suspicious for COVID-19
and testing returned a positive result. The patient
was not hypoxic and was discharged to home with
dexamethasone, though the reasoning for this prescription in the absence of hypoxia is unclear from
the record. Patient returned to the ED ﬁve days later
with persistent dry cough and new symptoms of
heartburn and singultus. He was thought to have
gastritis causing singultus and was discharged with
famotidine. Once again, one week later, he presented to the ED with complaints of fever, chills,
myalgia, and persistent hiccups. He was instructed
to ﬁnish his course of dexamethasone and was discharged to home again as he was not hypoxic. He
returned three days later with shortness of breath,
cough, nausea, vomiting, and persistent hiccups. On
this visit, patient was dyspneic and tachypneic,
requiring two liters of supplemental oxygen and
was admitted.
*

At the time of admission, the patient had grossly
normal lab results, except for an elevated d-dimer.
CTA chest showed bilateral inﬁltrates but no pulmonary embolism. Prior to this admission, patient
had been taking dexamethasone as an outpatient
for two weeks. The decision was made to continue
dexamethasone at 6 mg and Remdesevir as patient
was now hypoxic. The patient's singultus was so
severe it caused vomiting and he was unable to
tolerate a diet. He was given a trial of chlorpromazine 25 mg on the ﬁrst day, without improvement.
He tried various physical maneuvers including
breath holding, Valsalva maneuver, pressing on
eye orbits, and drinking water without improvement. On the second day, metoclopramide 10 mg
was tried without effect. Upon further investigation, dexamethasone-induced singultus was suspected as dexamethasone was the only new
medication prescribed and, at baseline, the patient
was on no home medications. The patient also
recalled his hiccups temporally started shortly after
he began the course of dexamethasone, but was he
unclear on the exact timing. Thus, dexamethasone
was discontinued.
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On the third day, the patient's hiccups persisted
despite discontinuation of dexamethasone and trial
of baclofen 5 mg was initiated. The next day the
patient reported mild improvement on hiccups but
continued to have difﬁculty tolerating oral intake.
The baclofen was increased to 10 mg TID and
olanzapine 5 mg BID was added. Following the ﬁrst
dose of combined baclofen and olanzapine, complete resolution of singultus was achieved. With
resolution of the hiccups, patient no longer required
supplemental oxygen. Patient was observed for 24 h
without singultus recurrence and was discharged
with 10 days of baclofen and olanzapine. Two weeks
after discharge, the patient was contacted and reported no recurrence of singultus.

2. Discussion
Hiccups, medically referred to as singultus, is a
condition that results from involuntary contraction
of the diaphragm and intercostal muscles.1 Singultus is usually a self-limiting condition which typically lasts less than 48 h but in rare cases, can persist
for greater than 48 h. Dexamethasone induced hiccup has been reported as an under recognized
condition. Various etiologies of singultus have been
reported including central nervous system disorders, vagus or phrenic nerve irritation, medicationinduced, toxic-metabolic, and psychogenic.2e6 This
case report identiﬁed medication-induced hiccups,
most speciﬁcally dexamethasone. The pathophysiology of singultus involves the hiccup reﬂex arc
which consists of afferent limb, central nervous
system, and efferent limb. Dopamine and gammaaminobutyric acid (GABA) neurotransmitters have
been documented in involvement of central nervous
system of the hiccup reﬂex arc.7 It has been proposed that dexamethasone decreases the threshold
for synaptic transmission in the midbrain resulting
in hiccups.8 The exact pathophysiology and other
factors associated with steroid-induced hiccups
remain unclear.
In order to treat singultus, both non-pharmacological and pharmacological cases have been reported. Non-pharmacological interventions such
as holding breath and Valsalva maneuver have
been documented.9 These maneuvers increase the
efferent vagal activity leading to negative feedback
of reﬂex arc involving phrenic and vagal nerve to
inhibit diaphragm contraction.9,10
The only drug approved by US Food and Drug
Administration for hiccups is chlorpromazine. It is
believed that chlorpromazine works by blocking the
dopamine receptors in the central nervous system.
When an approved drug is ineffective, other
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pharmacotherapy should be considered. Based on a
number of studies baclofen, metoclopramide, and
gabapentin have shown the most improvement
of hiccups, though, again, these drugs are not
approved for this indication.11 Baclofen and gabapentin are GABA analogs, and metoclopramide
blocks dopamine receptors affecting the hiccup reﬂex arc. Olanzapine is a serotonin antagonist, thus
possibly leading to the inhibition of the “serotonin
augmenting phrenic motoreneuronal activity reﬂex
arcs involved in the generation of hiccups within the
spinal cord.”12 Furthermore, olanzapine has a
dopamine antagonist effect contributing to the inhibition of the hiccup reﬂex arc.13 In this patient,
these medications were ineffective but the combination of baclofen and olanzapine resulted in resolution based on a case report of successful treatment
in intractable hiccups.14 It is possible that the combination of a GABA, serotonin, and dopamine
antagonist contributed to the resolution of intractable singultus in this patient.

3. Conclusion
Typically, hiccups are a benign condition which
can become detrimental if it continues to persist for
days. As the use of dexamethasone has increased
during the COVID-19 pandemic, it is important to
identify potential adverse effects. When refractory
hiccups are observed in a patient taking dexamethasone, a combination of baclofen and olanzapine can
be considered as an alternative pharmacotherapy.
Conﬂict of interest
There are no conﬂict of interest with this case
report.
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